Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CPRX NASDAQ:NBIX NYSE:NVS NASDAQ:PLRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPRXCatalyst Pharmaceuticals$20.73-0.5%$20.33$19.05▼$26.58$2.54B0.791.37 million shs1.12 million shsNBIXNeurocrine Biosciences$139.43+1.8%$136.98$84.23▼$154.61$13.83B0.211.20 million shs899,049 shsNVSNovartis$132.350.0%$123.57$96.06▼$133.55$279.58B0.641.85 million shs1.38 million shsPLRXPliant Therapeutics$1.49-2.0%$1.58$1.10▼$16.10$91.47M1.41.54 million shs441,251 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPRXCatalyst Pharmaceuticals0.00%+6.76%+2.71%-0.53%+4.20%NBIXNeurocrine Biosciences0.00%-3.50%-4.91%+7.16%+20.20%NVSNovartis0.00%+7.00%+2.04%+8.43%+16.20%PLRXPliant Therapeutics0.00%0.00%-18.28%+28.81%-86.82%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPRXCatalyst Pharmaceuticals$20.73-0.5%$20.33$19.05▼$26.58$2.54B0.791.37 million shs1.12 million shsNBIXNeurocrine Biosciences$139.43+1.8%$136.98$84.23▼$154.61$13.83B0.211.20 million shs899,049 shsNVSNovartis$132.350.0%$123.57$96.06▼$133.55$279.58B0.641.85 million shs1.38 million shsPLRXPliant Therapeutics$1.49-2.0%$1.58$1.10▼$16.10$91.47M1.41.54 million shs441,251 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPRXCatalyst Pharmaceuticals0.00%+6.76%+2.71%-0.53%+4.20%NBIXNeurocrine Biosciences0.00%-3.50%-4.91%+7.16%+20.20%NVSNovartis0.00%+7.00%+2.04%+8.43%+16.20%PLRXPliant Therapeutics0.00%0.00%-18.28%+28.81%-86.82%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPRXCatalyst Pharmaceuticals 3.00Buy$33.2060.15% UpsideNBIXNeurocrine Biosciences 2.81Moderate Buy$161.8916.11% UpsideNVSNovartis 2.10Hold$120.33-9.08% DownsidePLRXPliant Therapeutics 2.00Hold$8.19449.50% UpsideCurrent Analyst Ratings BreakdownLatest PLRX, NVS, CPRX, and NBIX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/27/2025CPRXCatalyst PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)9/27/2025NBIXNeurocrine BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)9/27/2025NVSNovartisWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy (B)9/27/2025PLRXPliant TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/22/2025NBIXNeurocrine BiosciencesWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform9/22/2025NBIXNeurocrine BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$161.00 ➝ $170.009/12/2025NVSNovartisThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral ➝ Sell$119.00 ➝ $118.009/5/2025NBIXNeurocrine BiosciencesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$144.00 ➝ $149.009/5/2025NBIXNeurocrine BiosciencesMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$158.00 ➝ $163.008/21/2025NVSNovartisDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/19/2025CPRXCatalyst PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 10/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPRXCatalyst Pharmaceuticals$491.73M5.16$2.43 per share8.52$6.10 per share3.40NBIXNeurocrine Biosciences$2.51B5.51$3.44 per share40.54$25.58 per share5.45NVSNovartis$50.32B5.56$10.70 per share12.37$21.59 per share6.13PLRXPliant Therapeutics$1.58M57.89N/AN/A$5.00 per share0.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPRXCatalyst Pharmaceuticals$163.89M$1.6512.569.730.8437.36%40.78%35.36%11/5/2025 (Estimated)NBIXNeurocrine Biosciences$341.30M$3.3841.2521.550.9913.88%13.22%9.39%10/29/2025 (Estimated)NVSNovartis$11.94B$6.8719.2615.021.8325.64%41.08%16.83%10/28/2025 (Estimated)PLRXPliant Therapeutics-$210.30M-$3.40N/AN/AN/AN/A-73.45%-55.66%11/6/2025 (Estimated)Latest PLRX, NVS, CPRX, and NBIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/29/2025Q3 2025NBIXNeurocrine Biosciences$1.55N/AN/AN/A$746.61 millionN/A10/28/2025Q3 2025NVSNovartis$2.28N/AN/AN/A$13.70 billionN/A8/7/2025Q2 2025PLRXPliant Therapeutics-$0.62-$0.71-$0.09-$0.71N/AN/A7/30/2025Q2 2025NBIXNeurocrine Biosciences$0.98$1.06+$0.08$1.06$653.09 million$687.50 million7/17/2025Q2 2025NVSNovartis$2.38$2.42+$0.04$2.06$13.94 billion$14.05 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCPRXCatalyst PharmaceuticalsN/AN/AN/AN/AN/ANBIXNeurocrine BiosciencesN/AN/AN/AN/AN/ANVSNovartis$2.601.96%N/A37.85%N/APLRXPliant TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPRXCatalyst PharmaceuticalsN/A6.716.55NBIXNeurocrine BiosciencesN/A3.203.10NVSNovartis0.530.820.62PLRXPliant Therapeutics0.1412.9912.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPRXCatalyst Pharmaceuticals79.22%NBIXNeurocrine Biosciences92.59%NVSNovartis13.12%PLRXPliant Therapeutics97.30%Insider OwnershipCompanyInsider OwnershipCPRXCatalyst Pharmaceuticals10.40%NBIXNeurocrine Biosciences4.80%NVSNovartis0.01%PLRXPliant Therapeutics6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPRXCatalyst Pharmaceuticals80122.39 million109.66 millionOptionableNBIXNeurocrine Biosciences1,80099.18 million94.92 millionOptionableNVSNovartis75,8832.11 billion2.11 billionOptionablePLRXPliant Therapeutics9061.39 million57.46 millionOptionablePLRX, NVS, CPRX, and NBIX HeadlinesRecent News About These CompaniesPliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Consensus Recommendation of "Hold" from AnalystsSeptember 27, 2025 | marketbeat.comAcadian Asset Management LLC Takes Position in Pliant Therapeutics, Inc. $PLRXSeptember 17, 2025 | marketbeat.comNuveen LLC Makes New Investment in Pliant Therapeutics, Inc. $PLRXSeptember 8, 2025 | marketbeat.comCormorant Asset Management LP Purchases Shares of 3,000,000 Pliant Therapeutics, Inc. $PLRXSeptember 6, 2025 | marketbeat.comNeedham Sticks to Its Hold Rating for Pliant Therapeutics (PLRX)August 21, 2025 | theglobeandmail.comCiti Reaffirms Their Hold Rating on Pliant Therapeutics (PLRX)August 21, 2025 | theglobeandmail.comPliant Therapeutics price target raised to $1.70 from $1.50 at CitiAugust 11, 2025 | msn.comPliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial ResultsAugust 7, 2025 | globenewswire.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Sangamo Biosciences (SGMO), Pliant Therapeutics (PLRX) and Stevanato Group (STVN)July 24, 2025 | theglobeandmail.comPliant Therapeutics Provides Update on BEACON-IPFJune 27, 2025 | globenewswire.comAlnylam, Pliant among stocks yet to face Q2 catalysts: Wells FargoJune 7, 2025 | msn.comPliant Therapeutics presents new fibrosis treatment dataMay 23, 2025 | investing.comPliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International ConferenceMay 21, 2025 | finance.yahoo.comPliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International ConferenceMay 21, 2025 | globenewswire.comPliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.comPliant Therapeutics announces workforce reductionMay 3, 2025 | uk.investing.comPliant Therapeutics Announces Workforce Reduction and Cost Saving Initiatives to Support Late-Stage Clinical TrialsMay 3, 2025 | nasdaq.comBay Area biotech company Pliant Therapeutics slashes staff after losing $655 million in valueMay 2, 2025 | msn.comPliant Axes 45% of Workforce To Save Cash, Support Late-Stage Clinical TrialsMay 2, 2025 | biospace.comBPliant Therapeutics cuts workforce by 45% after bexotegrast trial safety woesMay 2, 2025 | fiercebiotech.comFPliant Therapeutics Announces Strategic Realignment of Workforce and OperationsMay 1, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 2025Why Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 20253 Hot Tech Stocks With Bullish Charts and Ample UpsideBy Thomas Hughes | September 15, 2025Novartis' Moonshot Cancer Therapy Could Be Future Growth DriverBy Chris Markoch | September 9, 2025PLRX, NVS, CPRX, and NBIX Company DescriptionsCatalyst Pharmaceuticals NASDAQ:CPRX$20.73 -0.11 (-0.53%) Closing price 04:00 PM EasternExtended Trading$20.64 -0.09 (-0.41%) As of 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.Neurocrine Biosciences NASDAQ:NBIX$139.43 +2.40 (+1.75%) Closing price 04:00 PM EasternExtended Trading$140.02 +0.59 (+0.43%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.Novartis NYSE:NVS$132.35 -0.04 (-0.03%) Closing price 03:59 PM EasternExtended Trading$132.28 -0.07 (-0.06%) As of 05:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.Pliant Therapeutics NASDAQ:PLRX$1.49 -0.03 (-1.97%) Closing price 04:00 PM EasternExtended Trading$1.48 -0.01 (-0.67%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Marvell Insiders Buy Shares—Should Investors Follow Suit? Behind D-Wave's Massive Week (And Why Rivals Also Popped) Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? Best Stocks Under $15? 3 Low-Priced Picks With Upside After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught? Starbucks Stock Slumps; This Competitor Shows Strength Broadcom’s VMware Push Takes Aim at Microsoft, Google, & Amazon Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
